Transgene
Develops cancer immunotherapies using vaccines and oncolytic viruses.
TNG | PA
Overview
Corporate Details
- ISIN(s):
- FR0005175080
- LEI:
- 969500PDJW8N0FSGGK69
- Country:
- France
- Address:
- 400 BOULEVARD GONTHIER D'ANDERNACH, 67400 ILLKIRCH-GRAFFENSTADEN
- Website:
- https://www.transgene.fr/en/
Description
Transgene is a clinical-stage biotechnology company that designs and develops immunotherapies for the treatment of cancer. The company's strategy is based on two proprietary technology platforms. The myvac® platform is used to create individualized neoantigen therapeutic vaccines, such as its clinical candidate TG4050, which leverages advanced genetic engineering and artificial intelligence. The invir.IO® platform is dedicated to developing innovative, multifunctional oncolytic viruses engineered to directly destroy cancer cells and modulate the tumor microenvironment, thereby enhancing the patient's immune response against the tumor.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-17 17:45 |
Transgene annonce ses prochaines rencontres avec les investisseurs
|
French | 411.1 KB | ||
| 2025-12-17 17:45 |
Transgene to Participate in Upcoming Investor Meetings
|
English | 457.5 KB | ||
| 2025-11-27 00:15 |
Transgene annonce la reprise de la cotation de ses actions sur Euronext Paris …
|
French | 378.6 KB | ||
| 2025-11-27 00:15 |
Transgene announces the resume of trading of its shares on Euronext Paris as of…
|
English | 367.2 KB | ||
| 2025-11-26 23:32 |
Transgene Successfully Completes a Fundraising of c. €105 Million
|
English | 480.4 KB | ||
| 2025-11-26 23:32 |
Transgene réalise avec succès une levée de fonds d’environ 105 millions d’euros
|
French | 504.5 KB | ||
| 2025-11-25 22:01 |
DOCUMENT D'INFORMATION ETABLI CONFORMEMENT À L'ANNEXE IX DU REGLEMENT (UE) 2017…
|
French | 344.0 KB | ||
| 2025-11-25 21:42 |
Correction: Transgene annonce la suspension temporaire de la cotation de ses a…
|
French | 379.4 KB | ||
| 2025-11-25 21:42 |
Correction: Transgene Announces the Temporary Suspension of Trading of its Shar…
|
English | 373.6 KB | ||
| 2025-11-25 20:41 |
Transgene annonce la suspension temporaire de la cotation de ses actions sur E…
|
French | 384.5 KB | ||
| 2025-11-25 20:10 |
Correction: Transgene launches a fundraising campaign for approximately 105 mil…
|
English | 498.9 KB | ||
| 2025-11-25 20:10 |
Correction: Transgene lance une levée de fonds d’un montant d’environ 105 mill…
|
French | 539.4 KB | ||
| 2025-11-25 19:15 |
Transgene launches a fundraising campaign for approximately 105 million euros
|
English | 512.0 KB | ||
| 2025-11-25 19:15 |
Transgene lance une levée de fonds d’un montant d’environ 105 millions d’euros
|
French | 517.5 KB | ||
| 2025-11-06 08:30 |
Transgene présentera le potentiel de VacDesignR®, un outil bio-informatique bre…
|
French | 400.8 KB |
Automate Your Workflow. Get a real-time feed of all Transgene filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Transgene
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Transgene via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-30 | N/A | Other | Other | 30,898,876 | 32,999,999.57 EUR |
| 2023-05-26 | N/A | Other | Buy | 29,325 | N/A |
Peer Companies
